Abstract
Purpose
We assessed the efficacy and safety of performing intraocular surgery for refractory uveitis under adalimumab (ADA) therapy.
Study design
Single-center cohort study between 2016 and 2019.
Methods
In uveitis patients undergoing intraocular surgery under ADA treatment, we collected clinical data before surgery, and at the first visit, 6 months and last visit after surgery (follow-up 19.3 ± 8.1 months). Primary outcomes were visual acuity (VA) improvement in patients after cataract surgery, intraocular pressure (IOP) in patients after trabeculectomy and intraocular inflammation in all patients. Secondary outcomes were activated inflammation, vitreous opacity (OCV), uveitic macula edema (UME) and infection.
Results
Of 81 patients (161 eyes) initiated ADA therapy for uveitis, 19 patients (23 eyes) underwent intraocular surgery and were analyzed. Twelve of 18 eyes (66.6%) that underwent cataract surgery or vitrectomy with/without cataract surgery had improved VA at the last visit compared to before surgery. All 5 eyes that underwent trabeculectomy showed controlled IOP 6 months after surgery. Intraocular inflammation was resolved in 22 of 23 eyes at the first postoperative visit. Postoperative intraocular inflammation recurred in 3 eyes; 2 with UME, 1 with OCV. No eyes developed infection postoperatively. Preoperative ADA therapy duration was unrelated to relapse of intraocular inflammation.
Conclusion
Surgery for refractory uveitis under ADA treatment is safe and achieves good visual outcome and uveitis control if inflammation exists before surgery. ADA does not increase the risk of infections. Intraoperative findings of UME at surgery requires attention for postoperative relapse.
Similar content being viewed by others
References
Nussenblatt RB. Elements of the immune system and concepts of intraocular inflammatory disease pathogenesis. In: Nussenblatt RB, Whitcup SM, editors. Uveitis: fundamentals and clinical practice. 4th ed. China: Mosby Elsevier; 2010. p. 1–36.
Goto H, Mochizuki M, Yamaki K, Kotake S, Usui M, Ohno S. Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol. 2007;51:41–5.
Smith RE, Godfrey WA, Kimura SJ. Complications of chronic cyclitis. Am J Ophthalmol. 1976;82:277–82.
Okhravi N, Lightman SL, Towler HMA. Assessment of visual outcome after cataract surgery in patients with uveitis. Ophthalmology. 1999;106:710–22.
Merayo-Lloves J, Power WJ, Rodriguez A, Pedroza-Seres M, Foster CS. Secondary glaucoma in patients with uveitis. Ophthalmologica. 1999;213:300–4.
Mehta S, Linton MM, Kempen JH. Outcomes of cataract surgery in patients with uveitis: a systematic review and meta-analysis. Am J Ophthalmol. 2014;158:676-692.e7.
Shimizu A, Maruyama K, Yokoyama Y, Tsuda S, Ryu M, Nakazawa T. Characteristics of uveitic glaucoma and evaluation of its surgical treatment. Clin Ophthalmol. 2014;26:2383–9.
Bansal R, Gupta A, Gupta V, Mulkutkar S, Dogra M, Katoch D, et al. Safety and outcome of microincision vitreous surgery in uveitis. Ocul Immunol Inflamm. 2017;25:775–84.
Maruyama K, Hashida N, Koh S, Nakazawa T, Nishida K. Efficacy of vitreous surgery for prolonged cases of intraocular inflammatory disease. Nippon Ganka Gakkai Zasshi. 2018;122:393–9 (in Japanese).
Suzuki S. Cataract surgery during anti-TNF-α therapy (infliximab) for Behçet’s disease. J Clinic Exp Ophthalmol. 2013;04:328–33.
Fan F, Jia Z, Li K, Zhao X, Ma Q. Cataract surgery combined with micro-incision vitrectomy in patients with Behcet’s disease uveitis. BMC Ophthalmol. 2018;18:158.
Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factorα blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352–6.
Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125:1075–87.
Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behçet’s Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592–8.
Sakai T, Kanetaka A, Noro T, Tsuneoka H. Intraocular surgery in patients receiving infliximab therapy for Behçet disease. Jpn J Ophthalmol. 2010;54:360–1.
Noda E, Yamanishi S, Shiraishi A, Ohashi Y. Cataract surgery under infliximab therapy in a patient with Behçet’s disease. J Ocul Pharmacol Ther. 2009;25:467–70.
Khalil HEDM, el Gendy HA, Raafat HA, Haroun HE, Gheita TA, Bakir HM. The effectiveness of pre- and postoperative infliximab in controlling Behçet’s disease posterior uveitis in patients undergoing vitrectomy: a preliminary study. J Ophthalmol. 2017:8168369. https://pubmed.ncbi.nlm.nih.gov/28484648.
Goto H, Zako M, Namba K, Hashida N, Kaburaki T, Miyazaki M, et al. Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II trials. Ocul Immunol Inflamm. 2019;27:40–50.
Erckens RJ, Mostard RLM, Wijnen PAHM, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250:713–20.
Iannetti L, Accorinti M, Liverani M, Caggiano C, Abdulaziz R, Pivetti-Pezzi P. Optical coherence tomography for classification and clinical evaluation of macular edema in patients with uveitis. Ocul Immunol Inflamm. 2008;16:155–60.
Fabiani C, Vitale A, Rigante D, Emmi G, Bitossi A, Lopalco G, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019;38:407–15.
Jabs DA, Nussenblatt RB, Rosenbaum JT, Atmaca LS, Becker MD, Brezin AP, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–16.
Nussenblatt RB, Palestine AG, Chan C-C, Roberge F. Standardizatlon of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467–71.
Ministry of Health Labour and Welfare Designated Disease Study Group. Diagnostic criteria of Behcet’s disease (revised edition, 2003). In: Health science study: research on Behcet’s disease, final report for 2002. Tokyo: Ministry of Health, Labour and Welfare. 2003. p. 11–13.
Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647–52.
Ministry of Health Labour and Welfare Designated Disease Study Group. Diagnostic criteria of sarcoidosis. J Jpn Sarcoidosis Soc. 1991;201:159–62 (in Japanese).
Mochizuki M, Smith JR, Takase H, Kaburaki T, Acharya NR, Rao NA. Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol. 2019;103:1418–22.
Ohguro N, Sonoda K-H, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432–5.
Nussenblatt RB. Sympathetic ophthalmia. In: Nussenblatt RB, Whitcup SM, editors. Uveitis: fundamentals and clinical practice. 4th ed. China: Mosby Elsevier; 2010. p. 289–302.
Gupta V, Gupta A, Dogra MR. Posterior sympathetic ophthalmia: a single centre long-term study of 40 patients from North India. Eye (Lond). 2008;22:1459–64.
Yamane S, Sato S, Maruyama-Inoue M, Kadonosono K. Flanged intrascleral intraocular lens fixation with double-needle technique. Ophthalmology. 2017;124:1136–42.
Cairns JE. Trabeculectomy: preliminary report of a new method. Am J Ophthalmol. 1968;66:673–9.
Ciftci OU, Ozdemir O. Cataract extraction in Behçet’s disease. Acta Ophthalmol Scand. 1996;74:74–6.
Akova YA, Foster CS. Cataract surgery in patients with sarcoidosis-associated uveitis. Ophthalmology. 1994;101:473–9.
Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum. 2003;48:3013–22.
Wendling D, Balblanc J-C, Brousse A, Lohse A, Lehuede G, Garbuio P, et al. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis. 2005;64:1378–9.
Alfawaz A, Alrashidi S, Kalantan H, Al-Mezaine H, Abu AM. Cataract surgery under systemic infliximab therapy in patients with refractory uveitis associated with Behcet disease. Ann Saudi Med. 2014;34:328–33.
Levin MH, Pistilli M, Daniel E, Gangaputra SS, Nussenblatt RB, Rosenbaum JT, et al. Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology. 2014;121:588–95.
St. Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:1451–9.
Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerré T, et al. Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015;79:286–97.
Acknowledgements
This work was supported by a Grand-in-Aid for Scientific Research (C) 16K11330 and 19K09959 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
K. Kunimi, Financial Support (AbbVie, Eisai, Santen); Y. Usui, Financial Support (AbbVie, Eisai, Santen); K. Tsubota, None; T. Kezuka, None; H. Goto, Advisory board (AbbVie).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Corresponding author: Yoshihiko Usui
Supplementary Information
Below is the link to the electronic supplementary material.
About this article
Cite this article
Kunimi, K., Usui, Y., Tsubota, K. et al. Intraocular surgery under adalimumab therapy in patients with refractory uveitis: a single center study of 23 eyes. Jpn J Ophthalmol 65, 836–842 (2021). https://doi.org/10.1007/s10384-021-00871-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-021-00871-3